Compare Neurocrine Biosciences Inc (NBIX) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Taskus Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Taskus Inc trades at $7.59 (market cap $700.49M). The key difference: Neurocrine Biosciences Inc is far larger — about 22.5× Taskus Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | TASK | |
|---|---|---|
Market Cap | $15.77B | $700.49M |
Sector | Health | Technology |
52-Week High | $185.50 | $18.03 |
52-Week Low | $123.10 | $4.57 |
Enterprise Value | $15.78B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
TaskUs (TASK) trades at $7.65, down 3.29% today, with technical indicators showing neutral momentum. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income of $102.28M, yielding attractive valuation ratios including a P/E of 6.59 and P/S of 0.58. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.28 expected, driven by AI Services growth.
The stock presents value opportunity with discounted multiples and analyst consensus target of $8.00 (4.6% upside). Risks include client concentration and competitive pressures in digital services. Institutional interest remains positive with Dimensional Fund increasing holdings by 12.8% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
